Top

International Ophthalmology

Published in:

Open Access 01-06-2020 | Statins | Review

Inflammatory mediators of proliferative vitreoretinopathy: hypothesis and review

Authors: Ying Dai, Chenghua Dai, Tao Sun

Published in: International Ophthalmology | Issue 6/2020

Abstract

Purpose

To review the role of inflammatory mediators in proliferative vitreoretinopathy (PVR) development and the current treatment for PVR prevention.

Methods

A PubMed search was carried out using these keywords “PVR,” “inflammatory mediators,” “growth factors,” “cytokines” and “treatment.” Studies regarding inflammatory mediators and PVR therapy were included and published up to December 2019.

Results

Inflammatory mediators, namely growth factors and cytokines, have been implicated in the occurrence and development of PVR. Among various inflammatory mediators, transforming growth factor-β, platelet-derived growth factor, interleukin-6, interleukin-8 and tumor necrosis factor-α are considered to be particularly important. In this review, we focus on the hypothesis that growth factors and cytokines are involved in the development of PVR, and current treatment for the prevention of PVR.

Conclusion

We support the hypothesis that growth factors and cytokines may participate in the complex process of PVR development. More importantly, the identification of inflammatory mediators provides novel and efficacious therapeutic targets for the treatment of PVR.

Hilton G et al (1983) The classification of retinal detachment with proliferative vitreoretinopathy. Ophthalmology 90(2):121–125CrossRef

Moysidis SN, Thanos A, Vavvas DG (2012) Mechanisms of inflammation in proliferative vitreoretinopathy: from bench to bedside. Mediat Inflamm 2012:815937CrossRef

Ciprian D (2015) The pathogeny of proliferative vitreoretinopathy. Rom J Ophthalmol 59(2):88–92PubMedPubMedCentral

Pennock S, Haddock LJ, Eliott D, Mukai S, Kazlauskas A (2014) Is neutralizing vitreal growth factors a viable strategy to prevent proliferative vitreoretinopathy? Prog Retin Eye Res 40:16–34CrossRefPubMed

Pastor JC, Rojas J, Pastor-Idoate S, Di Lauro S, Gonzalez-Buendia L, Delgado-Tirado S (2016) Proliferative vitreoretinopathy: a new concept of disease pathogenesis and practical consequences. Prog Retin Eye Res 51:125–155CrossRefPubMed

Girard P, Mimoun G, Karpouzas I, Montefiore G (1994) Clinical risk factors for proliferative vitreoretinopathy after retinal detachment surgery. Retina 14(5):417–424PubMedCrossRef

Cardillo JA, Stout JT, LaBree L, Azen SP, Omphroy L, Cui JZ, Kimura H, Hinton DR, Ryan SJ (1997) Post-traumatic proliferative vitreoretinopathy. The epidemiologic profile, onset, risk factors, and visual outcome. Ophthalmology 104(7):1166–1173PubMedCrossRef

Feng K, Hu Y, Wang C, Shen L, Pang X, Jiang Y, Nie H, Wang Z, Ma Z (2013) Risk factors, anatomical, and visual outcomes of injured eyes with proliferative vitreoretinopathy: eye injury vitrectomy study. Retina 33(8):1512–1518PubMedCrossRef

Sadaka A, Giuliari GP (2012) Proliferative vitreoretinopathy: current and emerging treatments. Clin Ophthalmol (Auckl, NZ) 6:1325–1333

10.

Ryan SJ (1985) The pathophysiology of proliferative vitreoretinopathy in its management. Am J Ophthalmol 100(1):188–193PubMedCrossRef

11.

Kwon OW, Song JH, Roh MI (2016) Retinal detachment and proliferative vitreoretinopathy. Dev Ophthalmol 55:154–162PubMedCrossRef

12.

Campochiaro PA, Sugg R, Grotendorst G, Hjelmeland LM (1989) Retinal pigment epithelial cells produce PDGF-like proteins and secrete them into their media. Exp Eye Res 49(2):217–227PubMedCrossRef

13.

Tikhonovich MV, Iojleva EJ, Gavrilova SA (2015) The role of inflammation in the development of proliferative vitreoretinopathy. Klin Med (Mosk) 93(7):14–20

14.

Guenther SR, Schumann RG, Hagenau F, Wolf A, Priglinger SG, Vogt D (2019) Comparison of surgically excised premacular membranes in eyes with macular pucker and proliferative vitreoretinopathy. Curr Eye Res 44(3):341–349PubMedCrossRef

15.

Carrington L, McLeod D, Boulton M (2000) IL-10 and antibodies to TGF-β2 and PDGF inhibit RPE-mediated retinal contraction. Invest Ophthalmol Vis Sci 41(5):1210–1216PubMed

16.

Rouberol F, Chiquet C (2014) Proliferative vitreoretinopathy: pathophysiology and clinical diagnosis. J Fr Ophtalmol 37(7):557–565PubMedCrossRef

17.

Ricker LJ, Altara R, Goezinne F, Hendrikse F, Kijlstra A, La Heij EC (2011) Soluble apoptotic factors and adhesion molecules in rhegmatogenous retinal detachment. Invest Ophthalmol Vis Sci 52(7):4256–4262PubMedCrossRef

18.

Ricker LJ, Kijlstra A, Kessels AG, de Jager W, Liem AT, Hendrikse F, La Heij EC (2011) Interleukin and growth factor levels in subretinal fluid in rhegmatogenous retinal detachment: a case-control study. PLoS ONE 6(4):e19141PubMedPubMedCentralCrossRef

19.

Symeonidis C, Papakonstantinou E, Androudi S, Georgalas I, Rotsos T, Karakiulakis G, Diza E, Dimitrakos SA (2014) Comparison of interleukin-6 and matrix metalloproteinase expression in the subretinal fluid and the vitreous during proliferative vitreoretinopathy: correlations with extent, duration of RRD and PVR grade. Cytokine 67(2):71–76PubMedCrossRef

20.

Kon CH, Occleston NL, Aylward GW, Khaw PT (1999) Expression of vitreous cytokines in proliferative vitreoretinopathy: a prospective study. Invest Ophthalmol Vis Sci 40(3):705–712PubMed

21.

Robbins SG, Mixon RN, Wilson DJ, Hart CE, Robertson JE, Westra I, Planck SR, Rosenbaum JT (1994) Platelet-derived growth factor ligands and receptors immunolocalized in proliferative retinal diseases. Invest Ophthalmol Vis Sci 35(10):3649–3663PubMed

22.

Rasier R, Gormus U, Artunay O, Yuzbasioglu E, Oncel M, Bahcecioglu H (2010) Vitreous levels of VEGF, IL-8, and TNF-α in retinal detachment. Curr Eye Res 35(6):505–509PubMedCrossRef

23.

Limb GA, Alam A, Earley O, Green W, Chignell AH, Dumonde DC (1994) Distribution of cytokine proteins within epiretinal membranes in proliferative vitreoretinopathy. Curr Eye Res 13(11):791–798PubMedCrossRef

24.

Kumar A, Li X (2018) PDGF-C and PDGF-D in ocular diseases. Mol Aspects Med 62:33–43PubMedCrossRef

25.

Bastiaans J, van Meurs JC, Mulder VC, Nagtzaam NM, Smits-te Nijenhuis M, Dufour-van den Goorbergh DC, van Hagen PM, Hooijkaas H, Dik WA (2014) The role of thrombin in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 55(7):4659–4666PubMedCrossRef

26.

Morescalchi F, Duse S, Gambicorti E, Romano MR, Costagliola C, Semeraro F (2013) Proliferative vitreoretinopathy after eye injuries: an overexpression of growth factors and cytokines leading to a retinal keloid. Mediat Inflamm 2013:269787CrossRef

27.

Martins T, Eusebio N, Correia A, Marinho J, Casares F, Pereira PS (2017) TGFβ/Activin signalling is required for ribosome biogenesis and cell growth in Drosophila salivary glands. Open Biol 7(1):160258PubMedPubMedCentralCrossRef

28.

Sefat F, Youseffi M, Khaghani SA, Soon CF, Javid F (2016) Effect of transforming growth factor-β3 on mono and multilayer chondrocytes. Cytokine 83:118–126PubMedCrossRef

29.

Pasquale LR, Dorman-Pease ME, Lutty GA, Quigley HA, Jampel HD (1993) Immunolocalization of TGF-beta 1, TGF-beta 2, and TGF-beta 3 in the anterior segment of the human eye. Invest Ophthalmol Vis Sci 34(1):23–30PubMed

30.

Lutty GA, Merges C, Threlkeld AB, Crone S, McLeod DS (1993) Heterogeneity in localization of isoforms of TGF-β in human retina, vitreous, and choroid. Invest Ophthalmol Vis Sci 34(3):477–487PubMed

31.

Hoerster R, Muether PS, Vierkotten S, Hermann MM, Kirchhof B, Fauser S (2014) Upregulation of TGF-β1 in experimental proliferative vitreoretinopathy is accompanied by epithelial to mesenchymal transition. Graefes Arch Clin Exp Ophthalmol 252(1):11–16PubMedCrossRef

32.

Yao H, Ge T, Zhang Y, Li M, Yang S, Li H, Wang F (2019) BMP7 antagonizes proliferative vitreoretinopathy through retinal pigment epithelial fibrosis in vivo and in vitro. FASEB J 33(3):3212–3224PubMedCrossRef

33.

Dvashi Z, Goldberg M, Adir O, Shapira M, Pollack A (2015) TGF-β1 induced transdifferentiation of rpe cells is mediated by TAK1. PLoS ONE 10(4):e0122229PubMedPubMedCentralCrossRef

34.

Rojas J, Fernandez I, Pastor JC, Maclaren RE, Ramkissoon Y, Harsum S, Charteris DG, Van Meurs JC, Amarakoon S, Ruiz-Moreno JM, Rocha-Sousa A, Brion M, Carracedo A (2013) A genetic case-control study confirms the implication of SMAD7 and TNF locus in the development of proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 54(3):1665–1678PubMedCrossRef

35.

Saika S, Yamanaka O, Nishikawa-Ishida I, Kitano A, Flanders KC, Okada Y, Ohnishi Y, Nakajima Y, Ikeda K (2007) Effect of Smad7 gene overexpression on transforming growth factor β-induced retinal pigment fibrosis in a proliferative vitreoretinopathy mouse model. Arch Ophthalmol 125(5):647–654PubMedCrossRef

36.

Choi K, Lee K, Ryu SW, Im M, Kook KH, Choi C (2012) Pirfenidone inhibits transforming growth factor-β1-induced fibrogenesis by blocking nuclear translocation of Smads in human retinal pigment epithelial cell line ARPE-19. Molecular vision 18:1010–1020PubMedPubMedCentral

37.

Yang S, Yao H, Li M, Li H, Wang F (2016) Long non-coding RNA MALAT1 mediates transforming growth factor β1-induced epithelial-mesenchymal transition of retinal pigment epithelial cells. PLoS ONE 11(3):e0152687PubMedPubMedCentralCrossRef

38.

Sanabria Ruiz-Colmenares MR, Pastor Jimeno JC, Garrote Adrados JA, Telleria Orriols JJ, Yugueros Fernandez MI (2006) Cytokine gene polymorphisms in retinal detachment patients with and without proliferative vitreoretinopathy: a preliminary study. Acta Ophthalmol Scand 84(3):309–313PubMedCrossRef

39.

Chen X, Xiao W, Liu X, Zeng M, Luo L, Wu M, Ye S, Liu Y (2014) Blockade of Jagged/Notch pathway abrogates transforming growth factor β2-induced epithelial-mesenchymal transition in human retinal pigment epithelium cells. Curr Mol Med 14(4):523–534PubMedCrossRef

40.

Chen X, Ye S, Xiao W, Luo L, Liu Y (2014) Differentially expressed microRNAs in TGFβ2-induced epithelial-mesenchymal transition in retinal pigment epithelium cells. Int J Mol Med 33(5):1195–1200PubMedCrossRef

41.

Cao Q, Deji QZ, Liu YJ, Ye W, Zhaba WD, Jiang Q, Yan F (2019) The role of mechanical stretch and TGF-β2 in epithelial-mesenchymal transition of retinal pigment epithelial cells. Int J Ophthalmol 12(12):1832–1838PubMedPubMedCentralCrossRef

42.

Liu B, Song J, Han H, Hu Z, Chen N, Cui J, Matsubara JA, Zhong J, Lei H (2019) Blockade of MDM2 with inactive Cas9 prevents epithelial to mesenchymal transition in retinal pigment epithelial cells. Lab Invest 99(12):1874–1886PubMedCrossRef

43.

Begum G, O'Neill J, Chaudhary R, Blachford K, Snead DRJ, Berry M, Scott RAH, Logan A, Blanch RJ (2018) Altered decorin biology in proliferative vitreoretinopathy: a mechanistic and cohort study. Invest Ophthalmol Vis Sci 59(12):4929–4936PubMedCrossRef

44.

Mony S, Lee SJ, Harper JF, Barwe SP, Langhans SA (2013) Regulation of Na, K-ATPase β1-subunit in TGF-β2-mediated epithelial-to-mesenchymal transition in human retinal pigmented epithelial cells. Exp Eye Res 115:113–122PubMedCrossRef

45.

Cui JZ, Chiu A, Maberley D, Ma P, Samad A, Matsubara JA (2007) Stage specificity of novel growth factor expression during development of proliferative vitreoretinopathy. Eye (Lond) 21(2):200–208CrossRef

46.

Lei H, Hovland P, Velez G, Haran A, Gilbertson D, Hirose T, Kazlauskas A (2007) A potential role for PDGF-C in experimental and clinical proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 48(5):2335–2342PubMedCrossRef

47.

Lei H, Velez G, Hovland P, Hirose T, Kazlauskas A (2008) Plasmin is the major protease responsible for processing PDGF-C in the vitreous of patients with proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 49(1):42–48PubMedPubMedCentralCrossRef

48.

Agrawal RN, He S, Spee C, Cui JZ, Ryan SJ, Hinton DR (2007) In vivo models of proliferative vitreoretinopathy. Nat Protoc 2(1):67–77PubMedCrossRef

49.

Ikuno Y, Leong FL, Kazlauskas A (2000) Attenuation of experimental proliferative vitreoretinopathy by inhibiting the platelet-derived growth factor receptor. Invest Ophthalmol Vis Sci 41(10):3107–3116PubMed

50.

Zheng Y, Ikuno Y, Ohj M, Kusaka S, Jiang R, Cekic O, Sawa M, Tano Y (2003) Platelet-derived growth factor receptor kinase inhibitor AG1295 and inhibition of experimental proliferative vitreoretinopathy. Jpn J Ophthalmol 47(2):158–165PubMedCrossRef

51.

Li X, Ponten A, Aase K, Karlsson L, Abramsson A, Uutela M, Backstrom G, Hellstrom M, Bostrom H, Li H, Soriano P, Betsholtz C, Heldin CH, Alitalo K, Ostman A, Eriksson U (2000) PDGF-C is a new protease-activated ligand for the PDGF α-receptor. Nat Cell Biol 2(5):302–309PubMedCrossRef

52.

Andrews A, Balciunaite E, Leong FL, Tallquist M, Soriano P, Refojo M, Kazlauskas A (1999) Platelet-derived growth factor plays a key role in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 40(11):2683–2689PubMed

53.

Zhang H, Shang Q, An J, Wang C, Ma J (2019) Crocetin inhibits PDGF-BB-induced proliferation and migration of retinal pigment epithelial cells. Eur J Pharmacol 842:329–337PubMedCrossRef

54.

Zheng X, Du L, Wang H, Gu Q (2012) A novel approach to attenuate proliferative vitreoretinopathy using ultrasound-targeted microbubble destruction and recombinant adeno-associated virus-mediated RNA interference targeting transforming growth factor-β2 and platelet-derived growth factor-B. J Gene Med 14(5):339–347PubMedCrossRef

55.

Alderson MR, Pike BL, Harada N, Tominaga A, Takatsu K, Nossal GJ (1987) Recombinant T cell replacing factor (interleukin 5) acts with antigen to promote the growth and differentiation of single hapten-specific B lymphocytes. J Immunol 139(8):2656–2660PubMed

56.

Takatsu K, Kikuchi Y, Takahashi T, Honjo T, Matsumoto M, Harada N, Yamaguchi N, Tominaga A (1987) Interleukin 5, a T-cell-derived B-cell differentiation factor also induces cytotoxic T lymphocytes. Proc Natl Acad Sci USA 84(12):4234–4238PubMedCrossRef

57.

Dai Y, Wu Z, Sheng H, Zhang Z, Yu M, Zhang Q (2015) Identification of inflammatory mediators in patients with rhegmatogenous retinal detachment associated with choroidal detachment. Mol Vis 21:417–427PubMedPubMedCentral

58.

Holtkamp GM, Van Rossem M, de Vos AF, Willekens B, Peek R, Kijlstra A (1998) Polarized secretion of IL-6 and IL-8 by human retinal pigment epithelial cells. Clin Exp Immunol 112(1):34–43PubMedPubMedCentralCrossRef

59.

El-Ghrably IA, Dua HS, Orr GM, Fischer D, Tighe PJ (2001) Intravitreal invading cells contribute to vitreal cytokine milieu in proliferative vitreoretinopathy. Br J Ophthalmol 85(4):461–470PubMedPubMedCentralCrossRef

60.

Wang X, Miller EB, Goswami M, Zhang P, Ronning KE, Karlen SJ, Zawadzki RJ, Pugh EN Jr, Burns ME (2017) Rapid monocyte infiltration following retinal detachment is dependent on non-canonical IL6 signaling through gp130. J Neuroinflammation 14(1):121PubMedPubMedCentralCrossRef

61.

Lumi X, Jelen MM, Zupan A, Bostjancic E, Ravnik-Glavac M, Hawlina M, Glavac D (2019) Single nucleotide polymorphisms in retinal detachment patients with and without proliferative vitreoretinopathy. Retina 22(10):0000000000002477

62.

Banerjee S, Savant V, Scott RA, Curnow SJ, Wallace GR, Murray PI (2007) Multiplex bead analysis of vitreous humor of patients with vitreoretinal disorders. Invest Ophthalmol Vis Sci 48(5):2203–2207PubMedCrossRef

63.

Canataroglu H, Varinli I, Ozcan AA, Canataroglu A, Doran F, Varinli S (2005) Interleukin (IL)-6, interleukin (IL)-8 levels and cellular composition of the vitreous humor in proliferative diabetic retinopathy, proliferative vitreoretinopathy, and traumatic proliferative vitreoretinopathy. Ocul Immunol Inflamm 13(5):375–381PubMedCrossRef

64.

Aksunger A, Or M, Okur H, Hasanreisoglu B, Akbatur H (1997) Role of interleukin 8 in the pathogenesis of proliferative vitreoretinopathy. Ophthalmologica 211(4):223–225PubMedCrossRef

65.

El-Ghrably IA, Dua HS, Orr GM, Fischer D, Tighe PJ (1999) Detection of cytokine mRNA production in infiltrating cells in proliferative vitreoretinopathy using reverse transcription polymerase chain reaction. Br J Ophthalmol 83(11):1296–1299PubMedPubMedCentralCrossRef

66.

Zhao X, Lv C, Chen S, Zhi F (2018) A role for the non-receptor tyrosine kinase ACK1 in TNF-α-mediated apoptosis and proliferation in human intestinal epithelial caco-2 cells. Cell Biol Int 42(9):1097–1105PubMedCrossRef

67.

Zhang B, Wu T, Wang Z, Zhang Y, Wang J, Yang B, Zhao Y, Rao Z, Gao J (2015) p38MAPK activation mediates tumor necrosis factor-α-induced apoptosis in glioma cells. Mol Med Rep 11(4):3101–3107PubMedCrossRef

68.

Qi L, Zhi J, Zhang T, Cao X, Sun L, Xu Y, Li X (2015) Inhibition of microRNA-25 by tumor necrosis factor alpha is critical in the modulation of vascular smooth muscle cell proliferation. Mol Med Rep 11(6):4353–4358PubMedCrossRef

69.

Limb GA, Hollifield RD, Webster L, Charteris DG, Chignell AH (2001) Soluble TNF receptors in vitreoretinal proliferative disease. Invest Ophthalmol Vis Sci 42(7):1586–1591PubMed

70.

Jin M, He S, Worpel V, Ryan SJ, Hinton DR (2000) Promotion of adhesion and migration of RPE cells to provisional extracellular matrices by TNF-α. Invest Ophthalmol Vis Sci 41(13):4324–4332PubMed

71.

Wang CH, Cao GF, Jiang Q, Yao J (2012) TNF-α promotes human retinal pigment epithelial (RPE) cell migration by inducing matrix metallopeptidase 9 (MMP-9) expression through activation of Akt/mTORC1 signaling. Biochem Biophys Res Commun 425(1):33–38PubMedCrossRef

72.

Limb GA, Earley O, Jones SE, LeRoy F, Chignell AH, Dumonde DC (1994) Expression of mRNA coding for TNFα, IL-1 β and IL-6 by cells infiltrating retinal membranes. Graefes Arch Clin Exp Ophthalmol 232(11):646–651PubMedCrossRef

73.

Kahler CM, Herold M, Kaufmann G, Pischel AB, Schratzberger P, Reinisch N, Gruber B, Bellmann R, Dunzendorfer S, Kieselbach G, Wiedermann CJ (1998) Induction of arachidonic acid metabolite release by human fibroblasts in proliferative vitreoretinopathy. Eur J Pharmacol 341(1):111–117PubMedCrossRef

74.

Amara IE, Elshenawy OH, Abdelrady M, El-Kadi AO (2014) Acute mercury toxicity modulates cytochrome P450, soluble epoxide hydrolase and their associated arachidonic acid metabolites in C57Bl/6 mouse heart. Toxicol Lett 226(1):53–62PubMedCrossRef

75.

Parapuram SK, Ganti R, Hunt RC, Hunt DM (2003) Vitreous induces components of the prostaglandin E2 pathway in human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 44(4):1767–1774PubMedCrossRef

76.

Kuo HK, Chen YH, Huang F, Wu YC, Shiea J, Wu PC (2016) The upregulation of zinc finger protein 670 and prostaglandin D2 synthase in proliferative vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol 254(2):205–213PubMedCrossRef

77.

Tikhonovich MV, Erdiakov AK, Gavrilova SA (2018) Nonsteroid anti-inflammatory therapy suppresses the development of proliferative vitreoretinopathy more effectively than a steroid one. Int Ophthalmol 38(4):1365–1378PubMedCrossRef

78.

Vichai V, Suyarnsesthakorn C, Pittayakhajonwut D, Sriklung K, Kirtikara K (2005) Positive feedback regulation of COX-2 expression by prostaglandin metabolites. Inflamm Res 54(4):163–172PubMedCrossRef

79.

Tikhonovich M, Lyskin P, Ioyleva E, Gavrilova S (2016) Expression of cyclooxygenases and trophic and growth factors in epiretinal membranes at late stages of proliferative vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol 254(11):2277–2279PubMedCrossRef

80.

Kolko M, Kiilgaard JF, Wang J, Poulsen KA, Andreasen JR, la Cour M, Nissen MH, Heegaard S, Bazan NG, Prause JU (2009) Calcium-independent phospholipase A2 regulates retinal pigment epithelium proliferation and may be important in the pathogenesis of retinal diseases. Exp Eye Res 89(3):383–391PubMedCrossRef

81.

Oshima Y, Wakabayashi T, Sato T, Ohji M, Tano Y (2010) A 27-gauge instrument system for transconjunctival sutureless microincision vitrectomy surgery. Ophthalmology 117(1):93–102.e2PubMedCrossRef

82.

Leiderman YI, Miller JW (2009) Proliferative vitreoretinopathy: pathobiology and therapeutic targets. Semin Ophthalmol 24(2):62–69PubMedCrossRef

83.

Hui YN, Liang HC, Cai YS, Kirchhof B, Heimann K (1993) Corticosteroids and daunomycin in the prevention of experimental proliferative vitreoretinopathy induced by macrophages. Graefes Arch Clin Exp Ophthalmol 231(2):109–114PubMedCrossRef

84.

Rubsamen PE, Cousins SW (1997) Therapeutic effect of periocular corticosteroids in experimental proliferative vitreoretinopathy. Retina (Phila, Pa) 17(1):44–50CrossRef

85.

Jonas JB, Hayler JK, Panda-Jonas S (2000) Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy. Br J Ophthalmol 84(9):1064–1067PubMedPubMedCentralCrossRef

86.

Ahmadieh H, Feghhi M, Tabatabaei H, Shoeibi N, Ramezani A, Mohebbi MR (2008) Triamcinolone acetonide in silicone-filled eyes as adjunctive treatment for proliferative vitreoretinopathy: a randomized clinical trial. Ophthalmology 115(11):1938–1943PubMedCrossRef

87.

Yamakiri K, Sakamoto T, Noda Y, Nakahara M, Ogino N, Kubota T, Yokoyama M, Furukawa M, Ishibashi T (2008) One-year results of a multicenter controlled clinical trial of triamcinolone in pars plana vitrectomy. Graefes Arch Clin Exp Ophthalmol 246(7):959–966PubMedPubMedCentralCrossRef

88.

Banerjee PJ, Quartilho A, Bunce C, Xing W, Zvobgo TM, Harris N, Charteris DG (2017) Slow-release dexamethasone in proliferative vitreoretinopathy: a prospective. Randomized Control Clin Trial Ophthalmol 124(6):757–767

89.

Borhani H, Peyman GA, Rahimy MH, Thompson H (1995) Suppression of experimental proliferative vitreoretinopathy by sustained intraocular delivery of 5-FU. Int Ophthalmol 19(1):43–49PubMedCrossRef

90.

Asaria RH, Kon CH, Bunce C, Charteris DG, Wong D, Khaw PT, Aylward GW (2001) Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy: results from a randomized, double-blind, controlled clinical trial. Ophthalmology 108(7):1179–1183PubMedCrossRef

91.

Wickham L, Bunce C, Wong D, McGurn D, Charteris DG (2007) Randomized controlled trial of combined 5-Fluorouracil and low-molecular-weight heparin in the management of unselected rhegmatogenous retinal detachments undergoing primary vitrectomy. Ophthalmology 114(4):698–704PubMedCrossRef

92.

Sundaram V, Barsam A, Virgili G (2013) Intravitreal low molecular weight heparin and 5-Fluorouracil for the prevention of proliferative vitreoretinopathy following retinal reattachment surgery. Cochrane Database Syst Rev 1:CD006421

93.

Khawly JA, Saloupis P, Hatchell DL, Machemer R (1991) Daunorubicin treatment in a refined experimental model of proliferative vitreoretinopathy. Graefe's Arch Clin Exp Ophthalmol 229(5):464–467CrossRef

94.

Chen EP, Steinhorst UH, Samsa GP, Saloupis PT, Hatchell DL (1992) The effect of combined daunorubicin and triamcinolone acetonide treatment on a refined experimental model of proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 33(7):2160–2164PubMed

95.

Wiedemann P, Hilgers RD, Bauer P, Heimann K, Daunomycin Study Group (1998) Adjunctive daunorubicin in the treatment of proliferative vitreoretinopathy: results of a multicenter clinical trial. Am J Ophthalmol 126(4):550–559PubMedCrossRef

96.

Kumar A, Nainiwal S, Choudhary I, Tewari HK, Verma LK (2002) Role of daunorubicin in inhibiting proliferative vitreoretinopathy after retinal detachment surgery. Clin Exp Ophthalmol 30(5):348–351PubMedCrossRef

97.

Nassar K, Luke J, Luke M, Kamal M, Abd El-Nabi E, Soliman M, Rohrbach M, Grisanti S (2011) The novel use of decorin in prevention of the development of proliferative vitreoretinopathy (PVR). Graefes Arch Clin Exp Ophthalmol 249(11):1649–1660PubMedCrossRef

98.

Kita T, Hata Y, Arita R, Kawahara S, Miura M, Nakao S, Mochizuki Y, Enaida H, Goto Y, Shimokawa H, Hafezi-Moghadam A, Ishibashi T (2008) Role of TGF-β in proliferative vitreoretinal diseases and ROCK as a therapeutic target. Proc Natl Acad Sci USA 105(45):17504–17509PubMedCrossRef

99.

Heart Protection Study Collaborative Group (2002) MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360(9326):7–22CrossRef

100.

Coons JC (2002) Hydroxymethylglutaryl-coenzyme A reductase inhibitors in osteoporosis management. Ann Pharmacother 36(2):326–330PubMedCrossRef

101.

Campbell MJ, Esserman LJ, Zhou Y, Shoemaker M, Lobo M, Borman E, Baehner F, Kumar AS, Adduci K, Marx C, Petricoin EF, Liotta LA, Winters M, Benz S, Benz CC (2006) Breast cancer growth prevention by statins. Cancer Res 66(17):8707–8714PubMedCrossRef

102.

Kawahara S, Hata Y, Kita T, Arita R, Miura M, Nakao S, Mochizuki Y, Enaida H, Kagimoto T, Goto Y, Hafezi-Moghadam A, Ishibashi T (2008) Potent inhibition of cicatricial contraction in proliferative vitreoretinal diseases by statins. Diabetes 57(10):2784–2793PubMedPubMedCentralCrossRef

103.

Tuuminen R, Haukka J, Loukovaara S (2015) Statins in rhegmatogenous retinal detachment are associated with low intravitreal angiopoietin-2, VEGF and MMP-2 levels, and improved visual acuity gain in vitrectomized patients. Graefes Arch Clin Exp Ophthalmol 253(10):1685–1693PubMedCrossRef

104.

Loukovaara S, Sahanne S, Takala A, Haukka J (2018) Statin use and vitreoretinal surgery: findings from a Finnish population-based cohort study. Acta Ophthalmol 96(5):442–451PubMedCrossRef

Title: Inflammatory mediators of proliferative vitreoretinopathy: hypothesis and review
Authors: Ying Dai
Chenghua Dai
Tao Sun
Publication date: 01-06-2020
Publisher: Springer Netherlands
Keywords: Statins
Cytokines
Growth Factors
Growth Factors
Published in: International Ophthalmology / Issue 6/2020
Print ISSN: 0165-5701
Electronic ISSN: 1573-2630
DOI: https://doi.org/10.1007/s10792-020-01325-4

At a glance: The STEP trials

Springer Medicine

Inflammatory mediators of proliferative vitreoretinopathy: hypothesis and review

Abstract

Purpose

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2020

Efficacy of wheat hot pack (dry heat) and pottery hot pack (moist heat) on eyelid temperature and tissue blood flow in healthy eyes: a randomized control trial

Early changes of vascular lesions and responses to combined photodynamic therapy in patients with polypoidal choroidal vasculopathy

Diurnal variation of anterior segment parameters handled with Scheimpflug imaging in keratoconus patients

Comparison of the 1-year postoperative results of phacoemulsification–trabeculectomy and phacoemulsification–ExPRESS miniature shunt combined surgeries

Quantitative assessment of the effect of acute anaerobic exercise on macular perfusion via swept-source optical coherence tomography angiography in young football players

Scanning and transmission electron microscopy study of anterior lens epithelium in presenile cataract